68Ga-DOTATATE PET/CT与MRI在神经内分泌肿瘤肝转移中的对比:一项全面的病灶分析
这项回顾性研究评估了68Ga-DOTATATE PET、增强CT、PET/CT联合及MRI在36例胃肠胰神经内分泌肿瘤患者720个病灶(582个转移灶)中的逐病灶诊断效能。MRI敏感度94.0%、特异度94.2%,优于其他所有模态(均p<.001);PET/CT敏感度68.1%高于PET单独61.1%(p<.001),在PET判读基础上加做增强CT额外识别41个转移灶。MRI在亚厘米病灶检出上优势明显,结论认为MRI联合68Ga-DOTATATE PET/CT可提供最全面的评估。
要点
- MRI逐病灶敏感度94.0%、特异度94.2%,优于PET、CT及PET/CT(均p<.001)。
- 亚厘米病灶MRI敏感度:≤5 mm为83.3%、6-10 mm为99.6%,均高于PET/CT的34.8%和78.6%(p<.001)。
- 在PET判读基础上加做增强CT可额外识别41个转移灶。
核心结论
- MRI在检出单个神经内分泌肝转移灶方面优于68Ga-DOTATATE PET/CT,尤其是亚厘米病灶;诊断性CT可提升PET的检出效能,而MRI联合68Ga-DOTATATE PET/CT可提供最全面的评估。
研究设计与样本
- 回顾性研究,纳入36例组织学确诊的胃肠胰神经内分泌肿瘤患者,均于2017年8月至2023年12月间12周内完成增强MRI与68Ga-DOTATATE PET/CT检查;由三名阅片者分次对MRI、68Ga-DOTATATE PET、增强CT及PET/CT联合进行共识判读,病灶按大小分层,以影像随访或组织病理为参考标准,采用广义估计方程计算诊断效能指标。
诊断标准与关键数值
- 以影像随访或组织病理为参考标准:MRI敏感度94.0%、特异度94.2%,优于其他所有模态(均p<.001);PET/CT联合敏感度68.1%高于PET单独61.1%(p<.001);在PET判读基础上加做增强CT额外识别41个转移灶;病灶≤5 mm时MRI敏感度83.3%、PET/CT 34.8%,6-10 mm时MRI 99.6%、PET/CT 78.6%(p<.001);病灶>10 mm时MRI与PET/CT敏感度均为100%,PET单独为94.1%(p=.019)。
临床应用与阅片要点
- 作者认为MRI联合68Ga-DOTATATE PET/CT可提供最全面的评估,逐病灶分析中MRI对亚厘米肝转移灶的检出优于PET/CT。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the diagnostic performance of 68Ga-DOTATATE PET, contrast-enhanced CT, combined DOTATATE PET/CT, and MRI in detecting neuroendocrine liver metastases on a per-lesion basis and to assess the added value of diagnostic contrast-enhanced CT to PET interpretation as well as influence of lesion size.
MATERIALS AND METHODS: This retrospective study evaluated patients with histologically-confirmed gastroenteropancreatic neuroendocrine tumors who underwent both contrast-enhanced MRI and 68Ga-DOTATATE PET/CT within 12 weeks between August 2017 and December 2023. Three readers evaluated in consensus MRI, 68Ga-DOTATATE PET, contrast-enhanced CT, and combined PET/CT in separate sessions. Lesions were stratified by size. Diagnostic performance metrics were calculated using generalized estimating equations with reference standard of imaging follow-up or histopathology.
RESULTS: The study included 36 patients (mean age 66.4 ± 10.7 years, 55.6% male) with 720 lesions, of which 582 were metastases. MRI demonstrated superior performance (sensitivity 94.0%, specificity 94.2%) compared to all other modalities (all p < .001). Combined PET/CT showed superior sensitivity (68.1%) compared to PET alone (61.1%) (p < .001). The addition of diagnostic contrast-enhanced CT to PET interpretation identified 41 additional metastases. Size-stratified analysis revealed superior detection of subcentimeter lesions by MRI (sensitivity 83.3% for ≤ 5 mm, 99.6% for 6-10 mm) compared to PET/CT (34.8% and 78.6%, respectively; p < .001). For lesions > 10 mm, both MRI and PET/CT achieved 100% sensitivity, while PET alone reached 94.1% (p = .019).
CONCLUSION: MRI outperforms 68Ga-DOTATATE PET/CT in detecting individual neuroendocrine liver metastases, particularly for subcentimeter lesions. While diagnostic CT improves PET performance, the combination of MRI with 68Ga-DOTATATE PET/CT provides the most comprehensive assessment.
引用
- Herold A, Hajati A, Cao Y, et al. 68Ga-DOTATATE PET/CT versus MRI in neuroendocrine liver metastases: a comprehensive per-lesion analysis. Radiol Med. 2025. PMID: 40932677. doi:10.1007/s11547-025-02080-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。